Boehringer Ingelheim Enters into a Clinical Collaboration with Amgen to Evaluate BI 1701963 + Lumakras (sotorasib) for Locally Advanced or Metastatic NSCLC

September 17, 2021 Auto Bot Amgen, Boehringer Ingelheim, Clinical Trials, Lumakras, NSCLC, Sotorasib 0

Shots:

  • The companies collaborated to evaluate the synergistic effects of BI 1701963 (SOS1::pan-KRAS inhibitor) + Lumakras (KRAS G12C inhibitor) in a P-I trial for adult patients with LA or metastatic NSCLC
  • The companies will jointly share costs & manage the clinical development for combined therapy. Amgen will sponsor the trial
  • The preclinical data showed that the combination may result in increased anti-tumor activity based on complementary mechanisms of targeted oncology agents. BI 1701963 is currently being evaluated in P-I trials as monothx. and in combination with MEK inhibitors, KRASG12C inhibitors, or irinotecan for the treatment of advanced KRAS-mutated cancers

Click here to­ read full press release/ article | Ref: Boehringer Ingelheim | Image: Longevity Technology

The post Boehringer Ingelheim Enters into a Clinical Collaboration with Amgen to Evaluate BI 1701963 + Lumakras (sotorasib) for Locally Advanced or Metastatic NSCLC first appeared on PharmaShots.